Navigation Links
Catalyst Pharmaceutical Partners Licenses Exclusive Rights to New Class of GABA Aminotransferase Inhibitors From Northwestern University
Date:8/31/2009

CORAL GABLES, Fla., Aug. 31 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced today that the Company executed a license agreement under which it acquired exclusive worldwide rights to commercialize novel GABA aminotransferase inhibitors and derivatives of vigabatrin discovered by Northwestern University. These compounds may have applications to a broad range of neurological diseases, including addiction and epilepsy. Catalyst intends to pursue development work on an undisclosed, lead oral compound that has already been identified.

Under the terms of the agreement, Northwestern University granted Catalyst an exclusive worldwide license to certain composition of matter patents related to the new class of inhibitors and a patent application relating to derivatives of vigabatrin. Catalyst will be responsible for the continued research and development of any resulting product candidates. Northwestern University will receive from Catalyst an upfront payment, certain milestone payments relating to clinical development activities, and royalties on products resulting from the agreement. Additional terms of the agreement were not disclosed.

"The agreement with Northwestern University further demonstrates our continuing commitment to developing drugs for the treatment of addiction and obsessive-compulsive disorders and complements our current development platform in several areas," said Patrick McEnany, Chief Executive Officer of Catalyst. "First, this new class of GABA aminotransferase inhibitors is at least 200 times more potent than CPP-109, Catalyst's version of vigabatrin, in in vitro enzyme inhibition kinetics studies. The increased potency could enable the development of superior or alternative dosage forms compared with CPP-109.
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
2. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
3. Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results
4. Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction
5. CATalyst Summit Declared a Success: Its All About the Cat!
6. Cardiva Medical, Inc. to Present Highlights of the Boomerang Catalyst(TM) II System at the Investment in Innovation (In3) West Conference on February 29, 2008 in Las Vegas, NV
7. Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance
8. Case in Point: Patient Control of Data Critical Catalyst for Online Health Care Revolution
9. Catalyst Pharmaceutical Partners, Inc. Set to Join Russell Microcap(R) Index
10. Congress Approves ePrescribing Initiative in Medicare Reform Bill: Critical Catalyst in Driving a New Generation of Prescribing
11. CATalyst Council Forms to Address Feline Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... most popular vaccine brands for children may not be ... some cost factors when choosing vaccines, driving the market ... to a new study by University of Illinois researchers. ... driven by numerous factors," says Sheldon H. Jacobson, a ... science and of mathematics at the U. of I. ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... MD, was recently invited to submit a review ... Microbiology , one of the world,s foremost scientific ... specialist, and chair of the Department of Pediatrics ... analyzed the epidemiology and microbiology of co-infections during ... as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... about one in five infants in the United States ... first several months after birth. Research into probiotic use ... the April 1, 2014 issue of the British ... study, "Probiotics and Infant Colic," concluding that the use ... colic did not reduce crying or fussing in ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... the reason why isolated women are less vulnerable to falling ill ... ,The study is an eye-opener to the upcoming proof that ... a clue to the reason why socially isolated men are prone ... have shown a connection between stress and immune function. But this ...
... Bachoud-Lévi, M.D., and colleagues of the French national institute ... Huntington's disease// who previously received intracerebral fetal neural grafts ... ,But the same investigators reported today that ... years and then began to decline over the next ...
... at University of California have gained valuable insights about ... , a finding that may eventually accelerate current research ... is a joint effort by Dr. Frank Sauer (UCR ... Munich) and other researchers from University of California. The ...
... School of Public Health are one of the 14 ... Environmental Health Sciences// (NIEHS) to study the association between ... is a new study to control the rising obesity ... an individual’s body size. Working with various city departments, ...
... Research Institutes, Inc (NDRI) in New York City ... the role// of social supports, spirituality, religiousness, life ... recovery from addiction. The study reveals markedly improved ... a decrease in stress when people were inclined ...
... fear regarding the elevated risk of lymphoma associated with ... has found that such treatments may not confer an ... be seen in the latest issue of Arthritis & ... been found to increase with worsening of the chronic ...
Cached Medicine News:Health News:Women Portray Stronger Immune Response As Compared to Men, Study Suggests 2Health News:Fetal Neural Grafts Improves Motor and Cognitive Function in Huntington Patients 2Health News:Drug Addiction Recovery Buffered by Spirituality 2Health News:No Lymphoma Risk From Rheumatoid Arthritis Drugs 2
(Date:1/14/2014)... Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s ... a targeting guide with accompanying instrumentation to place and ... adjunct to the soft tissue (e.g. ligament) repair or ... tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
(Date:1/14/2014)... 2014 NineSigma , Inc., the leading innovation ... Leadership Summit , May 14-16, 2014 at the Global ... . This is the premier ... breakthrough achievements through open innovation. Participants will learn how ...
(Date:1/14/2014)... 14, 2014   Evidera , a leading provider of ... Center for Drug Evaluation and Research (CDER), U.S. Food ... guidance document for a patient-reported outcome (PRO) measure in ... Disease Tool [EXACT] for Measurement of Symptoms of Acute ...
Breaking Medicine Technology:Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
... Medarex, Inc. (Nasdaq:, MEDX ) announced today ... non-fucosylated version of MDX-060 that targets CD30, a,marker ... malignant cells of,Hodgkin,s lymphoma (HL) as well as ... potency and efficacy in cell lines when,compared to ...
... TEL AVIV, Israel, December 8 InspireMD, Ltd. announced,that ... use in Israel,by the Israeli Ministry of Health. , ... system presents a novel combination of a coronary,stent merged ... by an expandable, flexible fishnet style, micron level knit,sleeve ...
Cached Medicine Technology:Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma 2Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma 3MGuard(TM) Coronary Stent System Approved in Israel 2MGuard(TM) Coronary Stent System Approved in Israel 3
Flattened points in vertical plane, straight shafts, cross action, round handle....
... cross action. Round handle. Divides nucleus for ... Nuclei of any hardness can be pre-chopped ... of pre-chopped nuclear fragments is rapid. Risk ... diminished. Shortened ultra sound time and minimal ...
1.5 mm inner cutting edge....
Nucleus chopper....
Medicine Products: